Ordering Recommendation

Preferred molecular (DNA) test to confirm a diagnosis of Ehlers-Danlos type VI following clinical and/or biochemical presentation. For initial testing for EDS VI, refer to Ehlers-Danlos Syndrome Type VI Screen (0080351). This testing is NOT recommended to rule out other types of EDS.

Mnemonic

EDS-VI FGA

Methodology

Polymerase Chain Reaction/Sequencing

Performed

Varies

Reported

14-21 days

New York DOH Approval Status

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Specimen Required

Patient Preparation
Collect

Contact ARUP's genetic counselor at (800) 242-2787 x2141 prior to test submission.

Specimen Preparation
Storage/Transport Temperature
Unacceptable Conditions
Remarks
Stability

Reference Interval

Interpretive Data

Background Information for Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication:
Characteristics of Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI:
Kyphoscoliosis at birth or within the first year of life, severe neonatal hypotonia, thin hyperextensible and bruisable skin, atrophic scarring, joint hypermobility, and scleral fragility leading to increased risk for rupture of the globe. Increased risk for rupture of medium size arteries, and individuals with severe kyphoscoliosis are at increased risk for respiratory compromise.
Incidence:
Approximately 1 in 100,000 live births.
Inheritance:
Autosomal recessive.
Cause:
Lysyl hydroxylase deficiency due to pathogenic PLOD1 (procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase) gene mutations.
Clinical Sensitivity:
Not published; however, this test combination is expected to detect the majority of mutations.
Methodology:
Bidirectional sequencing of the entire coding region and intron/exon boundaries of the PLOD1 gene. Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large PLOD1 coding region deletions/duplications, including the common 8.3kb duplication of exons 10-16.
Analytical Sensitivity and Specificity:
99 percent.
Limitations
: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations and deep intronic mutations will not be detected. Large deletions/duplications of exon 9 will not be detected; large deletions/duplications of exons 1 and 5 may not be detected based on the breakpoints of the rearrangement. The breakpoints of large deletions/duplications will not be determined.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81479

Components

Component Test Code* Component Chart Name LOINC
2005560 EDS-VI (PLOD1) Seq, Del/Dup Specimen
2005561 EDS-VI (PLOD1) Seq, Del/Dup Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • EDS6
  • PLOD1
Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication (INACTIVE as of 05/17/21)